Molecular targeting to treat gastric cancer.
More papers using
Kurume, Japan. In World J Gastroenterol, 14 Nov 2014
UNLABELLED: Trastuzumab that targets human epidermal growth factor receptor 2 (HER2) protein is the only approved molecular targeting agent for treating gastric cancer in Japan and the outcomes have been favorable.
Treatment of eccrine porocarcinoma with metastasis to the parotid gland using intensity-modulated radiation therapy: a case report
In PLoS ONE, 2009
... Tucson, AZ), PR (1E2, prediluted, Ventana Medical Systems), EGFR (3C6, prediluted, Ventana Medical Systems), and HER2 (4B5, prediluted, Ventana Medical Systems). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
In Breast Cancer Research : BCR, 2008
... (SP1 antibody, Neomarkers, Fremont, CA, USA), PR (PgR 636 antibody, Dako, Carpinteria, CA, USA) and HER2 (A085 antibody, Dako). A case of primary small cell carcinoma of the breast
In Pathology Research International, 2006
... antibodies were used: estrogen receptor (Novocastra, clone 6F11, 1 : 100), progesterone receptor (Novocastra, clone 16, 1 : 100), c-erbB-2 oncoprotein (Dako, HER-2), mammoglobin (Dako, clone ... The annexins
In Breast Cancer Research : BCR, 2003
... HER2/neu immunohistochemistryDako, polyclonal ... Relationship between HER2 status and proliferation rate in breast cancer assessed by immunohistochemistry, fluorescence in situ hybridisation and standardised AgNOR analysis
In Pathology Research International, 2002
... hours in a humidity chamber using the following dilutions: p53 (clone DO-7, titer 1 : 50, Dako, Denmark), HER-2/neu (titer 1 : 50, Dako, Denmark), ER (clone 1D5, ...